title: [Experience with clinical administration of new drug Thrombovasim® in vascular surgery].
abstract: Recent years have witnessed an increased worldwide interest in medical use of unique naturally occurring enzymes - subtilisins possessing pronounced fibrinolytic and anti-inflammatory properties. The article deals with experience in clinical administration in vascular surgery of new therapeutic agent Thrombovasim® containing pegylated subtilisin as an active substance. Thrombovasim® has a favourable profile of safety, good tolerance and causes no severe haemorrhagic complications. The pharmacological action of Thrombovasim® consists in combination of the targeted effect on the fibrin carcass of the thrombus without participation of the own system of haemostasis and anti-inflammatory effect. In the Russian Federation Thrombovasim® has been used for 6 years predominantly in vascular pathology of lower limbs accompanied by the development of chronic venous insufficiency.
authors.affiliation: Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine Novosibirsk State Medical University of the RF Public Health Ministry, Novosibirsk, Russia.
authors.forename: P G
authors.initials: PG
authors.lastname: Madonov
authors.affiliation: Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine Novosibirsk State Medical University of the RF Public Health Ministry, Novosibirsk, Russia.
authors.forename: D N
authors.initials: DN
authors.lastname: Kinsht
authors.affiliation: Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine Novosibirsk State Medical University of the RF Public Health Ministry, Novosibirsk, Russia.
authors.forename: K I
authors.initials: KI
authors.lastname: Ershov
authors.affiliation: Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine Novosibirsk State Medical University of the RF Public Health Ministry, Novosibirsk, Russia.
authors.forename: M A
authors.initials: MA
authors.lastname: Shilova
authors.affiliation: Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine Novosibirsk State Medical University of the RF Public Health Ministry, Novosibirsk, Russia.
authors.forename: O N
authors.initials: ON
authors.lastname: Solov'ev
mesh_terms: D002908:Chronic Disease; D006801:Humans; D020860:Subtilisin / Q000008:administration & dosage*; D015912:Thrombolytic Therapy / Q000379:methods*; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000379:methods*; D014689:Venous Insufficiency / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D020860:Subtilisin